MedTrace Logo

Halodine Nasal Antiseptic in Patients With COVID-19

NCT04517188 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-10

No results posted yet for this study

Summary

Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent that has a long history of safe and effective use. Halodine Nasal Antiseptic is formulated for topical application PVP-I to nasal passages, and has demonstrated effectiveness against SARS-COV-2 in vitro - 99.99% inactivation within 15 seconds. This study will evaluate the ability of Halodine Nasal Antiseptic to impact SARS-CoV-2 in vivo.

Conditions

Interventions

DRUG

Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP

Single topical administration

Sponsors & Collaborators

  • Halodine LLC

    lead INDUSTRY

Principal Investigators

  • Samuel Barone, MD · Halodine LLC

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-07-01
Completion
2021-07-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04517188 on ClinicalTrials.gov